BioMarin Pharmaceutical Inc
BMRN57.810USD
-0.320-0.55%
收盘 02/09, 16:00（美东）报价延迟15分钟
11.10B总市值
21.26市盈率 TTM
关于 BioMarin Pharmaceutical Inc 公司
BioMarin Pharmaceutical Inc. is a global biotechnology company engaged in the development of genetic discovery into medicines that make an impact on the life of each patient. The Company has eight commercial therapies and a clinical and preclinical pipeline. Its commercial products include Vimizim (elosulfase alpha), Naglazyme (galsulfase), Palynziq (pegvaliase-pqpz), Brineura (cerliponase alfa), Aldurazyme (laronidase), Roctavian (valoctocogene roxaparvovec), Kuvan (sapropterin dihydrochloride), and Voxzogo (vosoritide). Vimizim is an enzyme replacement therapy for the treatment of MPS IVA, a lysosomal storage disorder. The Roctavian is an adeno-associated virus (AAV5) vector gene therapy designed to restore factor VIII plasma concentrations in patients with severe hemophilia A. Its key clinical programs include Vosoritide, BMN 333, BMN 390, BMN 351, BMN 349, and INZ-701. Its late-stage enzyme replacement therapy, INZ-701, is being developed for the treatment of ENPP1 deficiency.
BioMarin Pharmaceutical Inc简介
公司代码BMRN
公司名称BioMarin Pharmaceutical Inc
上市日期Jul 23, 1999
CEOHardy (Alexander)
员工数量3040
证券类型Ordinary Share
年结日Jul 23
公司地址770 Lindaro Street
城市SAN RAFAEL
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94901
电话14155066700
网址https://www.biomarin.com/
公司代码BMRN
上市日期Jul 23, 1999
CEOHardy (Alexander)
BioMarin Pharmaceutical Inc公司高管
名称
名称/职务
职务
持股
持股变动
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+6650.00%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.80K
-16570.00%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-3304.00%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+6650.00%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-2428.00%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+6650.00%
Ms. Barbara W. Bodem
Ms. Barbara W. Bodem
Independent Director
Independent Director
8.83K
+6650.00%
Dr. Athena M. Countouriotis, M.D.
Dr. Athena M. Countouriotis, M.D.
Independent Director
Independent Director
8.83K
+6650.00%
Mr. G. Eric Davis
Mr. G. Eric Davis
Executive Vice President, Secretary, Chief Legal Officer
Executive Vice President, Secretary, Chief Legal Officer
--
--
Mr. Brian R. Mueller, CPA
Mr. Brian R. Mueller, CPA
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
Chief Financial Officer, Executive Vice President, Principal Accounting Officer
--
--
查看更多
名称
名称/职务
职务
持股
持股变动
Mr. Richard A. (Randy) Meier
Mr. Richard A. (Randy) Meier
Non-Executive Independent Chairman of the Board
Non-Executive Independent Chairman of the Board
120.34K
+6650.00%
Mr. Alexander Hardy
Mr. Alexander Hardy
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
46.80K
-16570.00%
Dr. Gregory R Friberg, M.D.
Dr. Gregory R Friberg, M.D.
Executive Vice President, Chief Research & Development Officer
Executive Vice President, Chief Research & Development Officer
43.51K
-3304.00%
Mr. Robert J. (Bob) Hombach, CPA
Mr. Robert J. (Bob) Hombach, CPA
Independent Director
Independent Director
37.15K
+6650.00%
Ms. Cristin Hubbard
Ms. Cristin Hubbard
Executive Vice President, Chief Commercial Officer
Executive Vice President, Chief Commercial Officer
30.55K
-2428.00%
Dr. Maykin Ho, Ph.D.
Dr. Maykin Ho, Ph.D.
Independent Director
Independent Director
23.29K
+6650.00%
收入明细
单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
FY2018
业务USD
名称
营收
占比
Voxzogo
218.39M
28.70%
Vimizim
182.75M
24.02%
Naglazyme
122.03M
16.04%
Palynziq
108.78M
14.30%
Aldurazyme
53.71M
7.06%
其他
75.16M
9.88%
地区USD
名称
营收
占比
United States
274.11M
36.03%
Europe
195.18M
25.65%
Rest of the world
140.19M
18.43%
Latin America
97.62M
12.83%
ALDURAZYME net product revenues marked by Sanofi
53.71M
7.06%
业务
地区
业务USD
名称
营收
占比
Voxzogo
218.39M
28.70%
Vimizim
182.75M
24.02%
Naglazyme
122.03M
16.04%
Palynziq
108.78M
14.30%
Aldurazyme
53.71M
7.06%
其他
75.16M
9.88%
股东统计
更新时间: 2月6日 周五
更新时间: 2月6日 周五
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
8.98%
PRIMECAP Management Company
7.93%
Dodge & Cox
7.64%
State Street Investment Management (US)
4.56%
其他
61.48%
持股股东
持股股东
占比
The Vanguard Group, Inc.
9.41%
BlackRock Institutional Trust Company, N.A.
8.98%
PRIMECAP Management Company
7.93%
Dodge & Cox
7.64%
State Street Investment Management (US)
4.56%
其他
61.48%
股东类型
持股股东
占比
Investment Advisor
46.62%
Investment Advisor/Hedge Fund
37.53%
Hedge Fund
6.69%
Pension Fund
3.03%
Sovereign Wealth Fund
1.40%
Research Firm
1.35%
Individual Investor
0.74%
Bank and Trust
0.67%
Venture Capital
0.35%
其他
1.62%
机构持股
更新时间: 12月8日 周一
更新时间: 12月8日 周一
报告期
机构数
持股数
持股占比
持股变动
2025Q4
1342
187.67M
97.68%
-21.49M
2025Q3
1334
187.86M
111.13%
-2.15M
2025Q2
1344
190.17M
114.04%
-8.63M
2025Q1
1331
198.83M
113.78%
-19.35M
2024Q4
1317
196.49M
110.91%
+4.70M
2024Q3
1283
191.71M
111.61%
-4.43M
2024Q2
1271
195.66M
108.22%
+2.33M
2024Q1
1257
193.46M
109.63%
-14.58M
2023Q4
1275
195.75M
103.93%
+7.49M
2023Q3
1255
188.56M
102.57%
+2.75M
查看更多
股东持股明细
名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
18.49M
9.63%
-419.17K
-2.22%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
17.25M
8.98%
-790.94K
-4.38%
Sep 30, 2025
PRIMECAP Management Company
15.23M
7.93%
-542.89K
-3.44%
Sep 30, 2025
Dodge & Cox
14.69M
7.64%
-421.51K
-2.79%
Sep 30, 2025
State Street Investment Management (US)
8.76M
4.56%
-83.15K
-0.94%
Sep 30, 2025
Viking Global Investors LP
8.32M
4.33%
-3.97M
-32.28%
Sep 30, 2025
AQR Capital Management, LLC
5.93M
3.09%
+351.54K
+6.30%
Sep 30, 2025
Geode Capital Management, L.L.C.
3.54M
1.84%
+67.68K
+1.95%
Sep 30, 2025
Rothschild & Co Asset Management Europe SCS
2.63M
1.37%
+317.58K
+13.74%
Nov 30, 2025
Millennium Management LLC
2.63M
1.37%
-207.15K
-7.31%
Sep 30, 2025
查看更多
持股ETF
更新时间: 12月6日 周六
更新时间: 12月6日 周六
机构名称
占比
First Trust NYSE Arca Biotechnology Index Fund
3.44%
Global X Genomics & Biotechnology ETF
2.98%
Invesco Biotechnology & Genome ETF
2.47%
First Trust Health Care Alphadex Fund
2.15%
Goldman Sachs Future Health Care Equity ETF
2.15%
State Street SPDR S&P Biotech ETF
1.93%
WealthTrust DBS Long Term Growth ETF
1.86%
Alger Russell Innovation ETF
1.84%
Virtus LifeSci Biotech Products ETF
1.5%
VanEck Biotech ETF
1.4%
查看更多
First Trust NYSE Arca Biotechnology Index Fund
占比3.44%
Global X Genomics & Biotechnology ETF
占比2.98%
Invesco Biotechnology & Genome ETF
占比2.47%
First Trust Health Care Alphadex Fund
占比2.15%
Goldman Sachs Future Health Care Equity ETF
占比2.15%
State Street SPDR S&P Biotech ETF
占比1.93%
WealthTrust DBS Long Term Growth ETF
占比1.86%
Alger Russell Innovation ETF
占比1.84%
Virtus LifeSci Biotech Products ETF
占比1.5%
VanEck Biotech ETF
占比1.4%
分红派息
近5年累计派现
0.00
美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据
拆合股
公告日期
除权除息日
类型
比率
暂无数据
公告日期
除权除息日
类型
比率
暂无数据
